Numis Securities Ltd reiterated their buy rating on shares of Diurnal Group PLC (LON:DNL) in a research note released on Wednesday. They currently have a GBX 187 ($2.31) price objective on the stock.

Shares of Diurnal Group PLC (LON:DNL) opened at 140.00 on Wednesday. Diurnal Group PLC has a 52 week low of GBX 140.00 and a 52 week high of GBX 155.00. The company’s market cap is GBX 73.09 million. The firm’s 50-day moving average is GBX 142.22 and its 200-day moving average is GBX 145.60.

Diurnal Group PLC Company Profile

Diurnal Group plc is a United Kingdom-based specialty pharmaceutical company. The Company targets patient needs in chronic endocrine (hormonal) diseases, such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. The Company has two products in late-stage clinical development targeting adrenal disease: Chronocort and Infacort.

Receive News & Stock Ratings for Diurnal Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group PLC and related stocks with our FREE daily email newsletter.